Development of FHD-286 Monotherapy Will Not Continue in Metastatic Uveal Melanoma
Source: OncLive, June 2023
Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial (NCT04879017), further development in this indication will not be pursued, according to an announcement from Foghorn Therapeutics.
Data showed that among 47 of 73 patients who had target lesions available for evaluation, patient experienced a durable partial response, remaining on treatment for 16 months. Additionally, 9 patients experienced stable disease. Reductions in tumor target lesions were also reported in 8 patients.
Notably, reductions in circulating tumor DNA were observed. Preliminary data on immune modulation markers in the tumor microenvironment also support potential investigation of FHD-286 in combination with immune checkpoint inhibitors, according to the announcement.